SG11202011134XA - Dll3-cd3 bispecific antibodies - Google Patents
Dll3-cd3 bispecific antibodiesInfo
- Publication number
- SG11202011134XA SG11202011134XA SG11202011134XA SG11202011134XA SG11202011134XA SG 11202011134X A SG11202011134X A SG 11202011134XA SG 11202011134X A SG11202011134X A SG 11202011134XA SG 11202011134X A SG11202011134X A SG 11202011134XA SG 11202011134X A SG11202011134X A SG 11202011134XA
- Authority
- SG
- Singapore
- Prior art keywords
- dll3
- bispecific antibodies
- bispecific
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18176889 | 2018-06-09 | ||
EP18176888 | 2018-06-09 | ||
EP19159321 | 2019-02-26 | ||
PCT/EP2019/064942 WO2019234220A1 (en) | 2018-06-09 | 2019-06-07 | Dll3-cd3 bispecific antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202011134XA true SG11202011134XA (en) | 2020-12-30 |
Family
ID=66752128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202011134XA SG11202011134XA (en) | 2018-06-09 | 2019-06-07 | Dll3-cd3 bispecific antibodies |
Country Status (22)
Country | Link |
---|---|
US (3) | US11332541B2 (en) |
EP (1) | EP3802598A1 (en) |
JP (2) | JP7133043B2 (en) |
KR (1) | KR20210018311A (en) |
CN (1) | CN112513092A (en) |
AU (1) | AU2019280900A1 (en) |
BR (1) | BR112020022898A2 (en) |
CA (1) | CA3099956A1 (en) |
CL (1) | CL2020003105A1 (en) |
CO (1) | CO2020015172A2 (en) |
CR (1) | CR20200601A (en) |
EC (1) | ECSP20084864A (en) |
IL (1) | IL279235A (en) |
JO (1) | JOP20200313A1 (en) |
MA (1) | MA52742A (en) |
MX (1) | MX2020013348A (en) |
PE (1) | PE20210321A1 (en) |
PH (1) | PH12020552080A1 (en) |
SA (1) | SA520420748B1 (en) |
SG (1) | SG11202011134XA (en) |
TW (1) | TW202016151A (en) |
WO (1) | WO2019234220A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11667713B2 (en) | 2017-12-28 | 2023-06-06 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
US20210355197A1 (en) * | 2018-10-22 | 2021-11-18 | International Aids Vaccine Initiative | Anti-hiv antibodies |
TW202128756A (en) * | 2019-10-02 | 2021-08-01 | 德商百靈佳殷格翰國際股份有限公司 | Multi-specific binding proteins for cancer treatment |
CN115643806A (en) * | 2020-01-31 | 2023-01-24 | 璟尚生物制药公司 | Bispecific T cell engagers |
CN115397866A (en) * | 2020-03-31 | 2022-11-25 | 中外制药株式会社 | DLL 3-targeted multispecific antigen-binding molecules and uses thereof |
JP2023504675A (en) | 2020-05-19 | 2023-02-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Binding molecules for cancer treatment |
US20230203134A1 (en) * | 2020-05-20 | 2023-06-29 | The Trustees Of Columbia University In The City Of New York | Potent neutralizing antibodies against sars-cov-2, generation and uses thereof |
CN111551733A (en) * | 2020-05-29 | 2020-08-18 | 武汉大学 | Method for quantitatively detecting content of immune cell-derived extracellular vesicle PD-1, ELISA kit and using method |
AU2021345124A1 (en) | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
KR20230146521A (en) * | 2021-01-13 | 2023-10-19 | 메모리얼 슬로안 케터링 캔서 센터 | Antibody-pyrrolobenzodiazepine derivative conjugate |
EP4277665A1 (en) * | 2021-01-13 | 2023-11-22 | Memorial Sloan Kettering Cancer Center | Anti-dll3 antibody-drug conjugate |
US20220388986A1 (en) | 2021-04-29 | 2022-12-08 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
CN118076878A (en) | 2021-09-02 | 2024-05-24 | 勃林格殷格翰国际公司 | Method for determining future color values or corresponding attributes and device therefor |
WO2023151613A1 (en) * | 2022-02-10 | 2023-08-17 | 上海齐鲁制药研究中心有限公司 | Bispecific antigen-binding molecule and use thereof |
WO2023164474A1 (en) | 2022-02-23 | 2023-08-31 | Amgen Inc. | Cancer treatment targeting dll3 |
TW202405004A (en) * | 2022-06-23 | 2024-02-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Antigen-binding molecules that specifically bind to both dll3 and cd3 and the pharmaceutical use thereof |
US20240174641A1 (en) | 2022-10-26 | 2024-05-30 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
US20240174642A1 (en) | 2022-10-26 | 2024-05-30 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
US20240166629A1 (en) | 2022-10-26 | 2024-05-23 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
WO2024102693A2 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Il-18-fc fusion proteins |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
JP2919890B2 (en) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor |
GB9012995D0 (en) | 1990-06-11 | 1990-08-01 | Celltech Ltd | Multivalent antigen-binding proteins |
EP0563214A4 (en) | 1990-12-04 | 1994-08-17 | Wistar Inst | Bifunctional antibodies and method of preparing same |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
DK1136556T3 (en) | 1991-11-25 | 2005-10-03 | Enzon Inc | Process for the preparation of multivalent antigen-binding proteins |
WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
US5945311A (en) | 1994-06-03 | 1999-08-31 | GSF--Forschungszentrumfur Umweltund Gesundheit | Method for producing heterologous bi-specific antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
ES2176574T3 (en) | 1996-09-03 | 2002-12-01 | Gsf Forschungszentrum Umwelt | USE OF BI AND TRIESPECIFIC ANTIBODIES FOR INDUCTION OF TUMOR IMMUNITY. |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
DE69830901T2 (en) | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | A method for producing multispecific antibodies having heteromultimeric and common components |
ES2694002T3 (en) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polypeptide comprising an Fc region of variant human IgG1 |
US6649138B2 (en) | 2000-10-13 | 2003-11-18 | Quantum Dot Corporation | Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media |
DK1355919T3 (en) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molecules with longer half-lives, compositions and uses thereof |
US20020083888A1 (en) | 2000-12-28 | 2002-07-04 | Zehnder Donald A. | Flow synthesis of quantum dot nanocrystals |
JP4567436B2 (en) | 2001-07-20 | 2010-10-20 | ライフ テクノロジーズ コーポレーション | Luminescent nanoparticles and methods for their preparation |
EP1638510B1 (en) | 2003-07-01 | 2015-09-02 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
CA2609319C (en) | 2005-07-15 | 2014-02-04 | Nissan Chemical Industries, Ltd. | Thiophene compounds and thrombopoietin receptor activators |
AU2006301492B2 (en) * | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
RS56677B1 (en) | 2005-10-12 | 2018-03-30 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
AU2006340769A1 (en) | 2005-12-16 | 2007-10-04 | Genentech, Inc. | Method for diagnosing, prognosing and treating glioma |
US20070274985A1 (en) | 2006-05-26 | 2007-11-29 | Stefan Dubel | Antibody |
PE20080951A1 (en) | 2006-08-02 | 2008-09-11 | Novartis Ag | DERIVATIVES OF 2-OXO-ETHYL-AMINO-PROPIONAMIDE-PYRROLIDIN-2-IL-SUBSTITUTED AS INHIBITORS OF THE BINDING OF THE PROTEIN Smac TO THE INHIBITOR OF THE PROTEIN OF APOPTOSIS |
DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
EP2435473B1 (en) * | 2009-05-27 | 2013-10-02 | F.Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
EP2445936A1 (en) | 2009-06-26 | 2012-05-02 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
KR101764449B1 (en) | 2009-09-01 | 2017-08-02 | 제넨테크, 인크. | Enhanced protein purification through a modified protein a elution |
US8796425B2 (en) | 2009-12-23 | 2014-08-05 | Esbatech, An Alcon Biomedical Research Unit Llc | Method for decreasing immunogenicity |
HUE056313T2 (en) | 2010-01-29 | 2022-02-28 | Chugai Pharmaceutical Co Ltd | Anti-dll3 antibody |
AR080793A1 (en) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | BISPECIFIC ANTIBODIES |
EP3539988A3 (en) | 2010-05-27 | 2019-12-04 | Genmab A/S | Monoclonal antibodies against her2 |
CN103052649B (en) | 2010-07-29 | 2015-12-16 | Xencor公司 | There is the antibody of the iso-electric point of amendment |
WO2012106578A1 (en) | 2011-02-04 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc) |
MX342135B (en) | 2011-03-17 | 2016-09-14 | Ramot At Tel-Aviv Univ Ltd | Bi- and monospecific, asymmetric antibodies and methods of generating the same. |
WO2012143523A1 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecifc antibodies against her2 |
AU2012245116A1 (en) | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
BR112013032145B1 (en) | 2011-06-23 | 2022-09-20 | Ablynx N.V | TECHNIQUES TO PREDICT, DETECT AND REDUCE NON-SPECIFIED PROTEIN INTERFERENCE IN ASSAYS INVOLVING SINGLE VARIABLE DOMAINS OF IMMUNOGLOBULIN |
US10808040B2 (en) | 2011-08-17 | 2020-10-20 | Glaxo Group Limited | Modified proteins and peptides |
KR102106002B1 (en) | 2011-10-11 | 2020-05-07 | 제넨테크, 인크. | Improved assembly of bispecific antibodies |
EP2771364B1 (en) | 2011-10-27 | 2019-05-22 | Genmab A/S | Production of heterodimeric proteins |
DK2794905T3 (en) * | 2011-12-20 | 2020-07-06 | Medimmune Llc | MODIFIED POLYPEPTIDES FOR BISPECIFIC ANTIBODY BASIC STRUCTURES |
WO2013126746A2 (en) | 2012-02-24 | 2013-08-29 | Stem Centrx, Inc. | Novel modulators and methods of use |
NZ772318A (en) | 2012-04-20 | 2023-06-30 | Merus Nv | Methods and means for the production of ig-like molecules |
US20140072581A1 (en) * | 2012-07-23 | 2014-03-13 | Zymeworks Inc. | Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains |
EP2927321B1 (en) | 2012-11-27 | 2021-02-17 | Ajou University Industry-Academic Cooperation Foundation | Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof |
GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
CA2904805A1 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
ES2811923T3 (en) * | 2013-12-17 | 2021-03-15 | Genentech Inc | Anti-CD3 antibodies and methods of use |
ES2955736T3 (en) | 2014-05-06 | 2023-12-05 | Hoffmann La Roche | Production of heteromultimeric proteins using mammalian cells |
TW201609811A (en) * | 2014-07-31 | 2016-03-16 | 安美基研究(慕尼黑)公司 | Bispecific single chain antibody construct with enhanced tissue distribution |
GB201414823D0 (en) | 2014-08-20 | 2014-10-01 | Argen X Bv | Multispecific antibodies |
SG11201701423RA (en) | 2014-09-03 | 2017-03-30 | Boehringer Ingelheim Int | Compound targeting il-23a and tnf-alpha and uses thereof |
JP6576456B2 (en) | 2014-11-06 | 2019-09-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Fc region variants with modified FcRn binding properties and protein A binding properties |
JP2018519832A (en) * | 2015-06-30 | 2018-07-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Multispecific binding protein |
TWI793062B (en) * | 2015-07-31 | 2023-02-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for dll3 and cd3 |
TWI796283B (en) * | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for msln and cd3 |
US20190002563A1 (en) * | 2015-08-17 | 2019-01-03 | Macrogenics, Inc. | Bispecific Monovalent Diabodies That are Capable of Binding B7-H3 and CD3, and Uses Thereof |
EP3458478B1 (en) | 2016-05-18 | 2021-01-06 | Boehringer Ingelheim International GmbH | Anti pd-1 and anti-lag3 antibodies for cancer treatment |
KR20210006913A (en) * | 2018-04-11 | 2021-01-19 | 인히브릭스, 인크. | Multispecific polypeptide constructs with limited CD3 binding and related methods and uses |
KR20200083879A (en) | 2018-12-31 | 2020-07-09 | 삼성디스플레이 주식회사 | Color conversion substrate and display device |
-
2019
- 2019-06-06 TW TW108119701A patent/TW202016151A/en unknown
- 2019-06-07 SG SG11202011134XA patent/SG11202011134XA/en unknown
- 2019-06-07 AU AU2019280900A patent/AU2019280900A1/en active Pending
- 2019-06-07 JP JP2020568407A patent/JP7133043B2/en active Active
- 2019-06-07 US US16/434,188 patent/US11332541B2/en active Active
- 2019-06-07 KR KR1020207036859A patent/KR20210018311A/en not_active Application Discontinuation
- 2019-06-07 MA MA052742A patent/MA52742A/en unknown
- 2019-06-07 EP EP19728454.0A patent/EP3802598A1/en active Pending
- 2019-06-07 CA CA3099956A patent/CA3099956A1/en active Pending
- 2019-06-07 BR BR112020022898-2A patent/BR112020022898A2/en unknown
- 2019-06-07 PE PE2020001978A patent/PE20210321A1/en unknown
- 2019-06-07 WO PCT/EP2019/064942 patent/WO2019234220A1/en unknown
- 2019-06-07 CN CN201980051335.7A patent/CN112513092A/en active Pending
- 2019-06-07 CR CR20200601A patent/CR20200601A/en unknown
- 2019-06-07 JO JOP/2020/0313A patent/JOP20200313A1/en unknown
- 2019-06-07 MX MX2020013348A patent/MX2020013348A/en unknown
-
2020
- 2020-11-30 CL CL2020003105A patent/CL2020003105A1/en unknown
- 2020-12-02 CO CONC2020/0015172A patent/CO2020015172A2/en unknown
- 2020-12-03 PH PH12020552080A patent/PH12020552080A1/en unknown
- 2020-12-06 IL IL279235A patent/IL279235A/en unknown
- 2020-12-08 SA SA520420748A patent/SA520420748B1/en unknown
- 2020-12-30 EC ECSENADI202084864A patent/ECSP20084864A/en unknown
-
2022
- 2022-03-04 US US17/686,453 patent/US20220251236A1/en active Pending
- 2022-08-26 JP JP2022134954A patent/JP2022180379A/en active Pending
-
2023
- 2023-06-01 US US18/327,456 patent/US20230295337A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190375849A1 (en) | 2019-12-12 |
WO2019234220A1 (en) | 2019-12-12 |
IL279235A (en) | 2021-01-31 |
US20220251236A1 (en) | 2022-08-11 |
JP2021526816A (en) | 2021-10-11 |
CN112513092A (en) | 2021-03-16 |
CA3099956A1 (en) | 2019-12-12 |
PH12020552080A1 (en) | 2021-05-31 |
SA520420748B1 (en) | 2023-12-06 |
CR20200601A (en) | 2021-01-26 |
TW202016151A (en) | 2020-05-01 |
PE20210321A1 (en) | 2021-02-16 |
CL2020003105A1 (en) | 2021-06-11 |
KR20210018311A (en) | 2021-02-17 |
MX2020013348A (en) | 2021-03-09 |
CO2020015172A2 (en) | 2020-12-21 |
JOP20200313A1 (en) | 2020-12-06 |
EP3802598A1 (en) | 2021-04-14 |
AU2019280900A1 (en) | 2020-11-19 |
US20230295337A1 (en) | 2023-09-21 |
JP7133043B2 (en) | 2022-09-07 |
BR112020022898A2 (en) | 2021-02-23 |
JP2022180379A (en) | 2022-12-06 |
ECSP20084864A (en) | 2021-05-31 |
US11332541B2 (en) | 2022-05-17 |
MA52742A (en) | 2021-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279235A (en) | Dll3-cd3 bispecific antibodies | |
IL280780A (en) | Anti-tigit antibodies | |
PL3519437T3 (en) | Bispecific antibodies against p95her2 | |
IL279352A (en) | Il-11ra antibodies | |
IL280013A (en) | Anti-il36r antibodies | |
IL278010A (en) | Galectin-10 antibodies | |
GB201710838D0 (en) | Bispecific antibodies | |
ZA202004908B (en) | Bispecific antibody | |
IL277030A (en) | Antibodies | |
IL282756A (en) | Humanized anti-sirpα antibodies | |
SG11202106171WA (en) | Anti-btla antibodies | |
SG11202007735TA (en) | Anti-her2 antibodies | |
IL282355A (en) | Exosome-targeting bispecific antibodies | |
IL269577B (en) | Anti-pd-l1-anti-tim-3 bispecific antibodies | |
IL281594A (en) | Anti-klrg1 antibodies | |
IL286757A (en) | Bispecific antibodies | |
EP3693013A4 (en) | Bispecific antibody | |
IL286918A (en) | Bispecific antibody | |
GB201806084D0 (en) | Antibodies | |
GB201911211D0 (en) | Monoclonal antibodies against ambra-1 | |
EP3728311A4 (en) | Bispecific hiv-1-neutralizing antibodies | |
IL290050A (en) | Bispecific antibody | |
ZA202206008B (en) | Bispecific anti-ccl2 antibodies | |
GB201819952D0 (en) | Antibodies | |
GB201817309D0 (en) | Antibodies |